Clinical Observation of Topical Lidocaine Cream Combined With Moisturizing Cream in the Treatment of Atopic Dermatitis

NCT ID: NCT07067541

Last Updated: 2025-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-01

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Twenty-five patients with atopic dermatitis applied lidocaine cream plus a moisturizer to the right limb and lidocaine cream alone to the left limb, twice daily for four weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Group Type ACTIVE_COMPARATOR

Control lidocaine cream

Intervention Type DRUG

lidocaine cream alone

Experimental group

Group Type EXPERIMENTAL

Experimental lidocaine cream + moisturizer cream

Intervention Type DRUG

lidocaine cream + moisturizer cream

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control lidocaine cream

lidocaine cream alone

Intervention Type DRUG

Experimental lidocaine cream + moisturizer cream

lidocaine cream + moisturizer cream

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients aged 18-65 years.
2. Clinical diagnosis of atopic dermatitis according to the 2020 Guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China (symmetrical eczematous lesions for ≥6 months plus personal/family atopy history or elevated IgE/eosinophilia).
3. Voluntarily signed informed consent form.

Exclusion Criteria

1. Active heart, liver, kidney, or other serious systemic illness.
2. History of viral or bacterial infection within 1 month prior to enrollment.
3. Immunocompromised patients or those receiving systemic immunosuppressive therapy.
4. Known allergy to lidocaine, moisturizer components, or any study-related topical agents.
5. Pregnant or breastfeeding women.
6. Use of topical corticosteroids or calcineurin inhibitors within 2 weeks prior to enrollment.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital of Kunming Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tang Junting

Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-L-88

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Topical NanoDox® for Atopic Dermatitis
NCT02910011 COMPLETED PHASE2